{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:25:58Z","timestamp":1791822358020,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["202203045455"],"award-info":[{"award-number":["202203045455"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204414"],"award-info":[{"award-number":["82204414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022JJ30789"],"award-info":[{"award-number":["2022JJ30789"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022JJ30026"],"award-info":[{"award-number":["2022JJ30026"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022JJ40243"],"award-info":[{"award-number":["2022JJ40243"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105257","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:44:13Z","timestamp":1772984653000},"page":"105257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting metabolic reprogramming in multiple myeloma: Molecular mechanisms and potential therapeutic targets"],"prefix":"10.1016","volume":"222","author":[{"given":"Xueting","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guige","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-5051","authenticated-orcid":false,"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105257_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clml.2024.01.002","article-title":"An open-label phase I study of metformin and nelfinavir in combination with bortezomib in patients with relapsed and refractory multiple myeloma","volume":"24","author":"Alodhaibi","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2026.105257_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tibs.2014.02.004","article-title":"Serine and glycine metabolism in cancer","volume":"39","author":"Amelio","year":"2014","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","article-title":"The emerging role and targetability of the TCA cycle in cancer metabolism","volume":"9","author":"Anderson","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.critrevonc.2026.105257_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2018-05-850826","article-title":"IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies","volume":"133","author":"Bergaggio","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib5","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2018.207704","article-title":"A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis","volume":"104","author":"Besse","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105257_bib6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/bloodadvances.2022007383","article-title":"AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity","volume":"7","author":"Bloedjes","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105257_bib7","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1538-7445.AM2024-3641","article-title":"Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2\/ILT4 dual antagonist antibody, in patients with advanced solid tumors","volume":"84","author":"Blum","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-3316","article-title":"PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism","author":"Bonolo De Campos","year":"2025","journal-title":"Blood Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib10","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105257_bib11","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/0008-5472.CAN-22-2350","article-title":"CK1\u03b4 and CK1\u03b5 signaling sustains mitochondrial metabolism and cell survival in multiple myeloma","volume":"83","author":"Burger","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101611","article-title":"Iron regulates myeloma cell\/macrophage interaction and drives resistance to bortezomib","volume":"36","author":"Camiolo","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41419-022-05272-z","article-title":"Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105257_bib14","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","article-title":"FOXM1 regulates glycolysis and energy production in multiple myeloma","volume":"41","author":"Cheng","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105257_bib15","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1016\/j.apsb.2024.04.021","article-title":"Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis","volume":"14","author":"Cheng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105257_bib16","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-22-3481","article-title":"Histone methyltransferase NSD2 activates PKC\u03b1 to drive metabolic reprogramming and lenalidomide resistance in multiple myeloma","volume":"83","author":"Chong","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105257_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65312-y","article-title":"Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma","volume":"16","author":"Cogrossi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105257_bib18","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1038\/s41388-020-1345-x","article-title":"The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma","volume":"39","author":"Crawford","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105257_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/nu17010061","article-title":"The positive effects of training and time-restricted eating in gut microbiota biodiversity in patients with multiple myeloma","volume":"17","author":"Czerwi\u0144ska-Ledwig","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.critrevonc.2026.105257_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imr.12732","article-title":"Plasma cells: you are what you eat","volume":"288","author":"D\u2019Souza","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105257_bib21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105257_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molmed.2023.05.011","article-title":"Fatty acid binding proteins in multiple myeloma","volume":"29","author":"Diedrich","year":"2023","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.critrevonc.2026.105257_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2019.10.026","article-title":"Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis","volume":"72","author":"Ding","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1126\/science.122.3168.501","article-title":"Nutrition needs of mammalian cells in tissue culture","volume":"122","author":"Eagle","year":"1955","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105257_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-020-00196-w","article-title":"Targeting phosphoglycerate dehydrogenase in multiple myeloma","volume":"10","author":"Elsaadi","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib27","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","article-title":"Akt stimulates aerobic glycolysis in cancer cells","volume":"64","author":"Elstrom","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.26577","article-title":"Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma","volume":"97","author":"Evans","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib29","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147970","article-title":"Disrupting the reverse warburg effect as a therapeutic strategy in multiple myeloma","volume":"138","author":"Evans","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105257_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118852","article-title":"Metabolic markers for diagnosis and risk-prediction of multiple myeloma","volume":"265","author":"Fei","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.cell.2023.01.038","article-title":"What is cancer metabolism?","volume":"186","author":"Finley","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105257_bib33","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1126\/science.3103217","article-title":"Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes","volume":"235","author":"Flier","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105257_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12935-022-02742-4","article-title":"Integrated assessment of the clinical and biological value of ferroptosis-related genes in multiple myeloma","volume":"22","author":"Fu","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2026.105257_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","article-title":"vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells","volume":"8","author":"Gonsalves","year":"2020","journal-title":"Cancer Metab."},{"key":"10.1016\/j.critrevonc.2026.105257_bib36","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1182\/blood-2022-164966","article-title":"A multicenter phase I dose-escalation trial of a novel glutaminase inhibitor telaglenastat in combination with carfilzomib and dexamethasone in relapsed and refractory multiple myeloma","volume":"140","author":"Gonsalves","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94543","article-title":"Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies","volume":"3","author":"Gonsalves","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105257_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","article-title":"MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial","volume":"16","author":"Gounder","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105257_bib39","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/0008-5472.CAN-14-3804","article-title":"Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation","volume":"75","author":"Gu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-017-0392-4","article-title":"NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase","volume":"10","author":"Gu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105257_bib42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105257_bib43","first-page":"343","article-title":"Huachansu injection induces ferroptosis in multiple myeloma through NRF2\/HO-1 signaling pathway","author":"J","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-023-06036-z","article-title":"PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6","volume":"14","author":"Jia","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105257_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.critrevonc.2026.105257_bib46","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.7150\/ijbs.92274","article-title":"Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities","volume":"20","author":"Jiang","year":"2024","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib47","article-title":"Bone marrow stromal cells protect myeloma cells from ferroptosis through GPX4 deSUMOylation","volume":"611","author":"Jiang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105257_bib48","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41388-024-03020-5","article-title":"Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma","volume":"43","author":"Jiang","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105257_bib49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41419-025-07904-6","article-title":"METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression","volume":"16","author":"Jiang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105257_bib50","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel-lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105257_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.critrevonc.2026.105257_bib52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-019-1854-0","article-title":"Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma","volume":"10","author":"Kong","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105257_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8055","article-title":"Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm","author":"Kumar","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib54","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1535-7163.MCT-15-0798","article-title":"Elevated translation initiation factor eIF4E is an attractive therapeutic target in multiple myeloma","volume":"15","author":"Li","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105257_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-022-00326-6","article-title":"G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt\/\u03b2-catenin pathway","volume":"11","author":"Li","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib56","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.7150\/ijbs.113115","article-title":"NR5A2 (located on chromosome 1q32) inhibits ferroptosis and promotes drug resistance by regulating phospholipid remodeling in multiple myeloma","volume":"21","author":"Li","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155401","article-title":"Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1\/Nrf2\/HO-1 axis","volume":"128","author":"Li","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.critrevonc.2026.105257_bib58","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-023-01569-3","article-title":"Amino acid metabolism in health and disease","volume":"8","author":"Ling","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105257_bib59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00262-025-04031-1","article-title":"USP5 motivates immunosuppressive microenvironment in multiple myeloma by activating STAT2-PFKFB4-mediated glycolysis","volume":"74","author":"Long","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105257_bib60","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-020-0962-2","article-title":"The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma","volume":"35","author":"Longo","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105257_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2008.05.005","article-title":"Regulation of glutathione synthesis","volume":"30","author":"Lu","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.critrevonc.2026.105257_bib62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2026.105257_bib63","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105257_bib64","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2024025690","article-title":"Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib65","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2024027496","article-title":"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma","volume":"146","author":"Navarro","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib66","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111391118","article-title":"USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates","volume":"118","author":"Nguyen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105257_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40364-022-00376-2","article-title":"Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions","volume":"10","author":"Okabe","year":"2022","journal-title":"Biomark. Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13046-022-02250-3","article-title":"Pyrroline-5-carboxylate reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis","volume":"41","author":"Oudaert","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma","volume":"11","author":"Oudaert","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib70","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41375-023-02071-z","article-title":"CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1","volume":"38","author":"Pfeiffer","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105257_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.RES.44.1.127","article-title":"The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man","volume":"44","author":"Reivich","year":"1979","journal-title":"Circ. Res."},{"key":"10.1016\/j.critrevonc.2026.105257_bib73","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105257_bib74","doi-asserted-by":"crossref","first-page":"13421","DOI":"10.1073\/pnas.1402650111","article-title":"Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma","volume":"111","author":"Robert","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105257_bib75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40168-025-02045-6","article-title":"Microbiota-derived urolithin a in monoclonal gammopathies and multiple myeloma therapy","volume":"13","author":"Rodr\u00edguez-Garc\u00eda","year":"2025","journal-title":"Microbiome"},{"key":"10.1016\/j.critrevonc.2026.105257_bib76","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","article-title":"Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma","volume":"30","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib77","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib78","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-17-0263","article-title":"Ribonucleotide reductase catalytic subunit M1 (RRM1) as a novel therapeutic target in multiple myeloma","volume":"23","author":"Sagawa","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib79","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1600-0609.2007.00902.x","article-title":"First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma","volume":"79","author":"Schmidmaier","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib80","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-22-0723","article-title":"Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets","volume":"28","author":"Shah","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115720","article-title":"HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma","volume":"44","author":"Shen","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105257_bib82","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1073\/pnas.94.13.6658","article-title":"c-myc transactivation of LDH-a: Implications for tumor metabolism and growth","volume":"94","author":"Shim","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105257_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.869","article-title":"A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma","volume":"27","author":"Sondergaard","year":"2009","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib84","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1038\/s41388-021-01939-7","article-title":"IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma","volume":"40","author":"Song","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105257_bib85","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105257_bib86","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, Metabolism, and Cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105257_bib87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-022-01269-5","article-title":"A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors","volume":"15","author":"Su","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib88","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41698-025-01194-z","article-title":"EPAS1 increases SDHA to inhibit proliferation of multiple myeloma cells by restoring TCA cycle","volume":"9","author":"Sun","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: The ATOMIC-meso randomized clinical trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib90","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41571-024-00876-0","article-title":"Targeting cuproplasia and cuproptosis in cancer","volume":"21","author":"Tang","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2015.07.055","article-title":"SnapShot: interactions between B cells and T cells","volume":"162","author":"Tangye","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105257_bib92","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: The CANTATA randomized clinical trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib93","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105257_bib94","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.3390\/ijms25168949","article-title":"Different strategies to overcome resistance to proteasome inhibitors-a summary 20 years after their introduction","volume":"25","author":"Tyrna","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib95","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1158\/2643-3230.BCD-24-0203","article-title":"Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma","volume":"6","author":"Uribe-Herranz","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105257_bib96","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1038\/s41467-022-34654-2","article-title":"The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma","volume":"13","author":"Vdovin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105257_bib97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41419-025-07625-w","article-title":"LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105257_bib98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13046-024-02972-6","article-title":"MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis","volume":"43","author":"Wang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105257_bib99","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.freeradbiomed.2025.08.020","article-title":"Kaempferol induces mitophagy and disrupts iron metabolism via SFXN2 leading to apoptosis in multiple myeloma cells","volume":"240","author":"Wang","year":"2025","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.critrevonc.2026.105257_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116717","article-title":"The function and mechanism of clinical trial agent CPI-613 in multiple myeloma","volume":"232","author":"Wang","year":"2025","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105257_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2609455","article-title":"Clostridium butyricum alleviates multiple myeloma by remodeling the bone marrow microenvironment and inhibiting PI3K\/AKT pathway through the gut-bone axis","volume":"18","author":"Wang","year":"2026","journal-title":"Gut Microbes"},{"key":"10.1016\/j.critrevonc.2026.105257_bib102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105257_bib103","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16503","article-title":"Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma","volume":"190","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib104","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41467-022-31248-w","article-title":"Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance","volume":"13","author":"Xia","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105257_bib105","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1038\/s41467-024-50073-x","article-title":"Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis","volume":"15","author":"Xian","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105257_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117971","article-title":"SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation","volume":"256","author":"Xiang","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12929-022-00813-2","article-title":"Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma","volume":"29","author":"Xie","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105257_bib108","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1038\/s41467-024-50910-z","article-title":"Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma","volume":"15","author":"Xiong","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105257_bib109","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.19088","article-title":"PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion","volume":"203","author":"Xu","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40170-025-00373-7","article-title":"GDF15-mediated enhancement of the warburg effect sustains multiple myeloma growth via TGF\u03b2 signaling pathway","volume":"13","author":"Xue","year":"2025","journal-title":"Cancer Metab."},{"key":"10.1016\/j.critrevonc.2026.105257_bib111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.2025029950","article-title":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma","volume":"147","author":"Yan","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib112","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood.2024025694","article-title":"Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma","volume":"145","author":"Yang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib113","article-title":"CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma","author":"Yao","year":"2023","journal-title":"Blood 141 28412852"},{"key":"10.1016\/j.critrevonc.2026.105257_bib114","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood-2013-11-539395","article-title":"Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death","volume":"123","author":"Yin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105257_bib115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.freeradbiomed.2023.04.003","article-title":"Targeting ABCB6 with nitidine chloride inhibits PI3K\/AKT signaling pathway to promote ferroptosis in multiple myeloma","volume":"203","author":"Yin","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105257_bib116","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.plipres.2013.08.005","article-title":"Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids","volume":"52","author":"Zaidi","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.critrevonc.2026.105257_bib117","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bjh.18684","article-title":"Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase","volume":"201","author":"Zhang","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib118","article-title":"A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105257_bib119","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2023.11.019","article-title":"Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma","volume":"36","author":"Zhu","year":"2024","journal-title":"Cell Metab."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:39:28Z","timestamp":1778481568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":119,"alternative-id":["S1040842826001447"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105257","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting metabolic reprogramming in multiple myeloma: Molecular mechanisms and potential therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105257"}}